
Two of the best-known public figures to live with Parkinson’s disease each challenged part of the stereotype of who gets it. Michael J. Fox was diagnosed in 1991 at age 29. Muhammad Ali was diagnosed with Parkinson’s in 1984 and lived with the disease for more than three decades before he died in 2016.
Even so, Parkinson’s is still widely thought of as an older white man’s disease. I believe that image can shape who we suspect has it, who gets referred for specialty care, and who gets invited into research.
In my work in underrepresented communities like the Bronx in New York, I have seen how much outreach and education matter. I often hear concerns about the health care system from people whose communities have experienced exclusion and mistreatment. Trust is earned slowly, through relationships built over time: talking with people, not down to them, and showing up as part of the community, not simply arriving to tell people what to do. When people feel respected and included, conversations about care and research can change.
Consider Richard Huckabee, a Black man featured in the storybook The PD Movers: We Keep Moving. He first noticed major changes in his health in 2004. Over the next nine years, he underwent MRIs, full-body scans, and stress tests, was told he had Lyme disease and low vitamin D, and received medications that made his symptoms worse. In 2013, his doctor referred him to a neurologist, who diagnosed Parkinson’s after a neurologic examination that Huckabee described as lasting about 10 minutes. The book describes him as a young Black man who felt strongly that not fitting the stereotypical “old white male” profile was no excuse for such a long delay.
Real physician voices, twice a week
Free, and one click to unsubscribe.
His story is personal, but broader research has also documented disparities in Parkinson’s care. In a study of veterans newly diagnosed with Parkinson’s disease, African American veterans were diagnosed at a later stage than white veterans. The researchers found that under-reporting of disability accounted for much of the observed difference and concluded that it may help explain later diagnosis. The study was small (just 16 African American and 58 white veterans), but it carries an important lesson: What clinicians observe on examination may not always match how much disability a patient reports.
A 2021 study of 2,033 patients with Parkinson’s disease at one Chicago medical center found similar disparities. The 725 Black patients in the study were about four years older than white patients at their first recorded diagnosis there, were more likely to receive care through emergency or inpatient services, and were less likely to receive medications for parkinsonism.
Access to specialty care also differs. A 2023 study of 685,116 Medicare beneficiaries with Parkinson’s disease found that only 9.1 percent saw a movement disorder specialist in 2019. White beneficiaries saw one most often, at 9.4 percent, compared with 7.8 percent of Asian beneficiaries, 5.4 percent of Black beneficiaries, 4.6 percent of Hispanic beneficiaries, and 5.0 percent of beneficiaries categorized in the study as North American Native.
These findings do not prove that race itself causes worse outcomes. Access to care, income, geography, referral patterns, genetics, environmental exposures, and other factors may all contribute. What they do show is that people are not experiencing Parkinson’s diagnosis and care in the same way.
The same gaps run through research. A 2025 analysis of 328 randomized Parkinson’s clinical trials found substantial racial and ethnic underrepresentation. Among participants in U.S.-conducted trials with race reported, 2.1 percent were Black or African American. Among participants with ethnicity reported, 6.8 percent were Hispanic. The authors contrasted those proportions with 2021 U.S. demographic shares of 13.6 percent Black and 18.9 percent Hispanic.
Population percentages are not a perfect benchmark for what enrollment in every Parkinson’s study should look like. Disease prevalence, study design, and the scientific question all matter. But persistent underrepresentation limits what researchers can learn about how Parkinson’s affects different communities.
Rules already exist. Under National Institutes of Health (NIH) inclusion policy revised in July 2025, women and members of racial and ethnic minority groups are expected to be included in NIH-funded clinical research unless there is a clear and compelling justification for exclusion. But rules alone have not closed the gap.
What appears to help is meaningful patient and community engagement. Participation means joining a study. Engagement goes further: People with Parkinson’s and their care partners help researchers think about the questions being asked, how participation is structured and supported, and how studies are explained to the communities they hope to reach.
A 2018 systematic review published in The BMJ found that patient and public involvement modestly increased the odds of enrollment in clinical trials overall. In an exploratory analysis, the increase was larger when at least one person involved had lived experience of the condition being studied.
Parkinson’s-specific research points in the same direction. The FIRE-UP PD study tested community-based recruitment strategies at eight sites across the United States. Recruitment increased significantly at intervention sites compared with control sites among several historically underrepresented groups, including Black and African American participants who were not Hispanic/Latino, as well as several Hispanic/Latino groups.
A 2025 Chicago community-based study of 97 workshop participants provides another important clue. Participants identified transportation and financial incentives as factors that could make research participation easier, while longer visits and longer studies could discourage participation. Trust in medical researchers was generally high in this group and increased after the educational workshops.
Perhaps most striking, only 8.1 percent of respondents reported that a researcher or medical provider had ever asked them to participate in a Parkinson’s-specific research trial. That finding matters.
We sometimes talk about research participation as though patients are actively deciding not to participate. But people cannot consider an opportunity they do not know exists. They may not know that Parkinson’s research studies are available, that movement disorder specialists exist, that support groups or educational programs are nearby, or that some studies may help address practical participation barriers. Clinicians can help close that information gap.
Here is what I would ask of clinicians:
- Look past the stereotype: Keep Parkinson’s in mind for younger patients, women, and patients of every race. Pay attention when what you observe on examination does not match how much disability a patient reports.
- Refer early: When appropriate, connect patients with a movement disorder specialist who has focused expertise in Parkinson’s disease and related movement disorders.
- Do not assume patients know what is available: Tell patients and families about resources they may never encounter on their own: specialists, support groups, educational programs, clinical trials, and other research opportunities. A simple question (“Would you like to hear about research studies or Parkinson’s resources that may be available to you?”) can open a door that no one else has opened.
- Make patients partners, not just participants: Invite people living with Parkinson’s and their care partners to help researchers understand what makes a study realistic, understandable, and relevant to their communities. When people contribute their time and expertise to research design or community-engagement work, that contribution should be recognized and appropriately compensated.
- Talk openly about treatment and side effects: Some symptoms or medication effects may be difficult or embarrassing for patients to raise on their own. Creating space for those conversations can help patients receive better care.
This matters for a simple reason. Treatments are tested on the people who join studies, and clinical care is shaped by what those studies find. When communities are consistently underrepresented, researchers have less evidence about how well those findings apply to them.
The goal is not diversity for diversity’s sake. The goal is better science and better care.
More representative research can help us answer better questions: Are symptoms recognized at similar stages across communities? Does access to specialists affect when people receive treatment? Are genetic and environmental risk factors adequately understood across populations? Are the treatments we develop being studied in populations that reflect the people who may ultimately use them?
Health equity in Parkinson’s research will not come from one policy or one recruitment campaign. It requires relationships built over time among researchers, clinicians, community organizations, people living with Parkinson’s, and care partners.
Most of all, it requires us to stop assuming that people know what opportunities are available to them, and start making sure they are actually invited in.
Responsibility for the content rests solely with the author and does not imply agreement or approval by APDA.
Vicky Chan is a manager of programs and community engagement.
Your KevinMD author page is one of the top results for your name. Turn it into a premium profile, publish in 1 to 3 days, and get a guaranteed podcast slot.